Adient (NYSE:ADNT) Upgraded at BNP Paribas Exane
BNP Paribas Exane upgraded Adient (NYSE:ADNT) from "neutral" to "outperform" with a $26 price target, suggesting a 20.5% upside. This follows Adient's recent beat on quarterly earnings and revenue expectations. Despite mixed analyst sentiment overall, with a consensus "Hold" rating, institutional investors hold a …